Today, February 29th is celebrated World Rare Disease Day with the aim of raising awareness in society about these pathologies…
clinical trials
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
